Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,325 total articles
Aflac reported another strong quarter, and while the stock has rerated modestly, fundamentals and capital deployment justify a long entry. The insurer offers a durable dividend track record, reasonable valuation metrics (P/E ~15.8; EV/EBITDA ~11), and upside from higher investment income and AI-driven efficiency gains.
Conrad Industries (CNRD) reported $19.9M in 2025 net income ($3.96/diluted share) while backlog slid to $213.9M from $293.8M a year earlier. The shares are trading at about $23.20, implying a trailing P/E near 5.9. Technicals are soft but not broken; short-volume spikes and a one-day days-to-cover profile create episodic volatility. This trade targ…
Prudential (PRU) delivered a resilient outlook despite Japan-related volatility. At roughly $100, a 5.6% yield, sub-10x earnings and solid ROE make PRU a pragmatic swing trade for income-oriented traders. Entry at $99.00, stop $94.00, target $110.00 over a mid-term 45 trading day horizon.
Noah Holdings (NOAH) trades like a story of geopolitical and regulatory downside priced to perfection. At roughly $10.68, the stock carries a market cap of ~$748M, a P/E near 9.7 and a price-to-book around 0.51. Those numbers argue the market is over-discounting the firm's franchise value and earnings power. This trade idea offers a tactical long w…
Halozyme has quietly converted its enzyme platform into a high-margin royalty engine and is layering in M&A to accelerate growth. With 2026 guidance calling for >$1B in royalty revenue and adjusted EBITDA near $1.1B, the stock at ~$66 offers a tactical swing entry to capture a re-rating tied to continued partner sales and integration of Surf Bio. T…
Magna posted strong Q1 results, is streamlining lower-margin businesses and is returning capital while trading at reasonable multiples relative to cash-flow metrics. We like the risk/reward for a long trade that targets a move back toward the 52-week high as margins expand and adjusted EPS rises.
Microsoft's commercial AI stack and Azure demand are driving durable revenue leverage. Fundamentals - including $72.9B free cash flow, 30% ROE, and a $3.06T market cap - give the company scope to invest and defend share. This trade idea takes a constructive, risk-managed long on MSFT at $412 with a $490 target over the next 180 trading days and a $…
Slide Insurance combines rapid premium growth with unusually strong free cash flow and a low earnings multiple. At about $18.60 the stock trades at roughly 5x earnings and under 2x book, leaving room for upside as the company scales its specialty homeowners and landlord lines. The principal hazard is catastrophe exposure in 2026 hurricane season an…
Aris Mining (ARIS) has one of the steepest production growth profiles among mid-tier gold producers and is trading well below its 52-week high after a modest pullback. With a market cap of $3.57B, solid float and institutional interest, the setup favors a long trade that targets a re-test of the $23 area within a multi-month horizon while using a t…
Apple reported a strong earnings cadence that lifted the stock above $280. Solid free cash flow ($129.2B trailing) and a high-margin services mix underpin growth, but P/E near 33.5, a 52-week high test and potential supply or margin pressures argue for a disciplined entry with a nearby stop.
MTU Aero Engines (MTUAY) is trading near its 52-week low after a sharp pullback from February highs. The company's durable MRO franchise, exposure to next-gen propulsion programs, and a modest valuation (market cap $18.1B, PE ~15.5) make this an actionable mid-term long. Trade plan: enter at $167.50, stop $155.00, target $205.00 (mid-term, 45 tradi…
The iShares MSCI Japan ETF (EWJ) sits near its highs with constructive technicals and macro policy catalysts behind the rally. With a market cap of $20.29B, a PE of 19.6 and PB near 1.95, EWJ looks reasonably valued for continued upside tied to fiscal stimulus, corporate governance reforms and a weaker yen. This trade plan targets $95 with a $86 st…
Jet fuel is spiking and the air-transport sector is jittery, but LATAM's post-bankruptcy network rationalization, improving unit economics and a still-reasonable valuation argue for a measured long swing. This trade targets mean reversion back toward the mid-50s while protecting capital under an explicit stop.
Credo Technology is winning in high-speed electrical interconnects and just bought silicon photonics capability. Revenue and EPS growth are accelerating; market pricing already reflects a lot of optimism, but the combination of product-led market share and optical expansion makes Credo a compelling long-term trade with defined risk-management.
EverQuote (EVER) is seeing a fresh rally driven by improving marketing economics and heavy intraday volume. Strong profitability metrics (EPS $2.81), meaningful free cash flow ($90.3M), and an attractive EV/EBITDA of ~4.85 underpin an upgrade to a tactical long. Trade plan targets a mid-term upside while respecting short-term volatility and elevate…
DigitalOcean is riding outsized AI demand from developers and SMBs while aggressively expanding capacity. Recent prints show rapid AI ARR growth, institutional buying and a capital raise dedicated to infrastructure. Valuation is rich but the momentum and low days-to-cover short interest create a favorable risk/reward for a mid-term long. Entry at $…
Dycom just cleared its 52-week high and enters a new phase after closing its Power Solutions acquisition. With a record $9.5 billion backlog and fiscal 2027 revenue guide of $6.85-7.15 billion, the setup favors a mid-term buy. Trade plan, targets, and risks laid out below.
Micron surged into new territory after the 245TB Micron 6600 ION SSD and accelerating memory price inflation. Fundamentals are solid - $10.3B in free cash flow, ROE north of 33% and a sub-0.15 debt/equity - but the stock is stretched: current price $642.66, 52-week high $651.74, RSI ~82. My trade: trim size at $642.66, take profits to lock gains, r…
Lam Research reported record Q3 revenue of $5.84B and raised guidance, with memory capex and AI demand driving order flow. At a market cap near $348B and P/E ~48, the stock is richly priced but justified by roughly 30% growth expectations, exceptional returns on capital and improving margins. Trade plan: enter at $280.00, target $365.00, stop $245.…
Microsoft is transitioning from a narrative-weighted AI bet to a monetization-focused strategy. With a $3.05 trillion market cap, strong free cash flow ($72.9B), low leverage and enterprise-first distribution, MSFT looks buyable on dips. This trade expects AI revenue conversion to accelerate over the next 180 trading days as Microsoft reduces singl…
Alphabet is trading at an implied market cap of roughly $460B and sits at the center of a multiyear AI replatforming. This trade idea argues for a controlled long position that leans on Alphabet's enterprise AI lock-in, ad resilience and cloud AI momentum, while acknowledging regulatory and competitive headwinds. Exact trade plan included for a lon…
Fresenius Medical Care (FMS) is trading near its 52-week low while carrying a sub-1 P/B and single-digit P/E relative to its longer-term profile. Technicals are deeply oversold, and the stock yields roughly 2.5% with an upcoming ex-dividend date. This trade idea sets a precise entry, stop and target for a long-term rebound play over 180 trading day…
SEMHF has pulled back into the low $40s amid heavy shorting and technical weakness. The company’s razor-and-blades revenue mix (equipment sales followed by recurring consumables and service) suggests outsized recovery potential if China volumes and service contracts normalize. This trade targets a mean reversion toward the 50-day average and beyond…
Charter rates for LPG carriers have moved beyond the levels that underpinned my prior bull case. Dorian LPG's balance sheet, cash flow generation, and a healthy dividend create a favorable risk-reward for a mid-term long trade. Entry at $39.82, stop at $36.00, target $48.00 (mid-term 45 trading days).
Viking Therapeutics (VKTX) is a small-cap clinical-stage biotech with an injectable GLP-1/GIP dual agonist, VK2735, that has shown rapid weight loss and tolerability in early data. The market is pricing in big upside: the Street consensus sits near $93.59, implying roughly 170% from today's ~$30.87. This trade idea outlines a long position sized fo…
